Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HARMONIE: Nirsevimab to prevent RSV hospitalization in infants
2022-000099-20Phase 3Completed
- Sponsor
- Sanofi
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nirsevimab in respiratory syncytial virus disease (RSV) (2 arms), sponsored by Sanofi. Primary endpoint: Overall incidence of RSV LRTI hospitalization through the RSV season. Started Mar 2022; status: completed.
02
Drugs
nirsevimab
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2022-000099-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000099-20.